Teppei Hagino
Overview
Explore the profile of Teppei Hagino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Onda M, Hagino T, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2025 Mar;
PMID: 40087893
Bimekizumab, an interleukin (IL)-17A/IL-17F inhibitor, is effective for moderate-to-severe psoriasis. However, long-term maintenance of early treatment outcomes is not examined in real-world settings, with no analyses stratified by dosing intervals...
2.
Morita T, Ichiyama S, Ito M, Ozaki S, Arai T, Atsukawa M, et al.
J Nippon Med Sch
. 2025 Mar;
92(1):88-96.
PMID: 40058840
Background: Psoriasis is accompanied by systemic inflammation that includes the liver. The fibrosis-4 (FIB-4) index was developed to predict significant liver fibrosis. The present study evaluated the effects of biologics,...
3.
Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi S, et al.
Dermatitis
. 2025 Feb;
PMID: 39977111
Real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited. To evaluate the real-world effectiveness and safety of lebrikizumab on Japanese patients with AD. This...
4.
Takahashi Y, Hagino T, Saeki H, Fujimoto E, Kanda N
Dermatitis
. 2025 Feb;
PMID: 39937140
No abstract available.
5.
Hagino T, Saeki H, Fujimoto E, Kanda N
Dermatitis
. 2025 Feb;
PMID: 39932721
An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD), but its effectiveness on different anatomical sites and clinical signs remains unclear. To assess the effectiveness of tralokinumab on different...
6.
Hagino T, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2025 Feb;
PMID: 39916637
Real-world evidence on the long-term effectiveness of deucravacitinib, a selective tyrosine kinase 2 inhibitor for psoriasis, remains limited, particularly in patients with different histories of systemic treatments. We evaluated the...
7.
Hagino T, Saeki H, Fujimoto E, Kanda N
Dermatitis
. 2025 Feb;
PMID: 39907080
Some patients with moderate-to-severe atopic dermatitis (AD) show insufficient response to treatment with tralokinumab, an anti-interleukin-13 antibody. Identifying predictive factors for poor responders to tralokinumab can help optimize treatment strategies...
8.
Hagino T, Saeki H, Fujimoto E, Kanda N
J Am Acad Dermatol
. 2025 Jan;
PMID: 39880172
Background: Long-term (2 years) effectiveness of upadacitinib for atopic dermatitis (AD) is unknown in real-world practice. Objective: To evaluate 96-week real-world effectiveness of upadacitinib in Japanese patients with moderate-to-severe AD,...
9.
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2025 Jan;
PMID: 39873274
Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is effective for psoriasis. However, long-term real-world effectiveness stratified by age and body mass index (BMI) has not been precisely examined. This study...
10.
Yoneyama M, Hagino T, Saeki H, Fujimoto E, Kanda N
J Dermatol
. 2025 Jan;
PMID: 39797588
No abstract available.